How much water do I add to Danuglipron?

You can reconstitute Danuglipron with 0.5, 1, or 2 mL of bacteriostatic water. Each option produces a different concentration and syringe draw for the same dose. Use the calculator to see which is easiest to measure.

What does Danuglipron cost per dose?

Cost per dose depends on vial size, price paid, and your dose. Enter your vendor's price in the Danuglipron calculator to see cost per dose and monthly cost.

What is the reference dose for Danuglipron?

The commonly referenced range is 40 up to 200 mg per dose, taken daily. This is reference information, not a recommendation. Talk to a licensed clinician.

What are the side effects of Danuglipron?

Reported side effects of Danuglipron include: Stomach side effects.; It is not approved, and it is a pill rather than a peptide.. Severity and frequency vary by person and dose.

Who should not take Danuglipron?

Danuglipron is generally not appropriate for: Development has stopped, so it is not available and no prescriber is assessing anyone for it. Talk to a licensed clinician before starting.

New?New to peptides?Start here →

Decoding

Danuglipron_Dosage, benefits & legal status

Also known as PF-06882961

By the Peptide Decoding Editorial Team

Published July 22, 2026 · Updated July 25, 2026

An experimental weight-loss pill whose development was stopped over a liver-injury signal.

Weight loss (oral)Oral GLP-1 (small molecule)Investigational

InGLP-1 agonistsTaken without a needle

Dose40 up to 200 mg per dose

FrequencyDaily

RouteBy mouth (oral)

StatusInvestigational

MixYour choice, calculate it

CycledNo schedule. Development stopped in April 2025

Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.

What is Danuglipron?

Plain language first. The technical label stays, but it never stands alone.

Overview

It gives GLP-1-style appetite control without injections. It is in testing.

The technical version

Danuglipron is an oral GLP-1 receptor agonist and a small molecule, not a peptide, so it works as a pill.

What it's used for

An experimental appetite-lowering pill for weight loss, no needles. It is in testing.

How does Danuglipron work?

What it does in the body, and where.

Danuglipron was an attempt at an oral GLP-1 pill using a small molecule rather than a peptide. Development stopped.

01
It activated the GLP-1 receptor as a small molecule
The same approach that orforglipron went on to succeed with.
02
Development was halted in April 2025
Pfizer stopped the programme after a participant showed signs of drug-induced liver injury, which resolved when the drug was withdrawn.
03
It is here for reference, not as an option
The dose figures on this page are historical. This is not something you can obtain or should be seeking.

Receptors

Acts on one receptor.

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

Weight loss without injections. Development was discontinued in 2025, so nothing is approved or availableResearch only

The published record

Research index

Records indexed for Danuglipron

53 in humans, 25 of them original studies.

20 registered trials, 11 with posted results.

Browse the records

In animalsPro

In the labPro

ReviewsPro

Senior author sharePro

Counted from Europe PMC indexing, not read by a person. Human means indexed under humans, which includes reviews and work on human cells. Original studies exclude reviews and lab work on human cells.Last updated 12 September 2026.

Compound field notes

At a glance

Four things to know about Danuglipron

Evidence

Investigational

How much, and do you cycle it?

The range, and whether you take breaks.

40 up to 200 mg per dose, daily. No schedule. Development stopped in April 2025Discontinued

Pfizer ended the programme after a case of possible drug-induced liver injury, following the same fate as its sister compound the year before. Nothing about its dosing is worth planning around.

Compare this against the whole library →

How long does it stay in the body?

The half-life, and where the figure comes from.

About 8 hoursTrial protocol

Measured in participants with normal kidney function. A twice-daily oral small molecule rather than a peptide.

Source: NCT04616027 posted results. Saxena AR, et al. Nat Med 2021;27:1079-1087

You can compare this against the whole library to see where it sits.

What does it cost?

Typical dose and cost, in plain numbers.

Danuglipron is not injected

It is taken by mouth (oral). Phase 2b used 40 to 200 mg twice daily. Pfizer stopped development in April 2025 after a participant showed signs of liver injury, so this is a historical dose, not an option.

Cost per month

—

Cost per dose

—

Typical dose

40 mg–200 mg / doseDiscontinued

Pfizer statement on danuglipron →

How do you store it?

Before mixing, and after.

Room temperature. Cool, dry, out of light.

Danuglipron is taken as a pill or capsule. Keep it in its original container at room temperature, away from heat, humidity, and direct sun. No fridge or mixing needed. Check the expiration date on the bottle.

What are the side effects and cautions?

Known cautions and warnings for this compound.

Who should avoid it

Check these before anything else.

Development has stopped, so it is not available and no prescriber is assessing anyone for it

Stop and get help

These are emergencies. Seek care.

Yellowing of the skin or eyes, dark urine, or severe unexplained tiredness, which can signal liver injury
Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing

Common effects

Expected, and usually mild.

Nausea, vomiting, and diarrhea, which were severe enough in the earlier twice-daily version that more than half of participants stopped taking it

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

Is Danuglipron approved?

And where the numbers on this page come from.

No. Danuglipron is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.

Approval status
Investigational
Route
By mouth (oral)
Checked
September 2026

What has happened recently

Pfizer discontinued danuglipron in April 2025. One participant experienced a possible drug-induced liver injury, which resolved after stopping. An earlier twice-daily version had already been dropped in 2023 over how badly people tolerated it.

You can compare this against the whole library, or read how to check a seller.

DoseFrom published clinical trials. Not approved by a regulator for this dose.
Vial sizeFrom what vendors typically list; not a recommendation.
Sources
Pfizer, topline phase 2b results for oral danuglipron in adults with obesity Efficacy and safety of danuglipron in adults with obesity, randomized placebo-controlled dose-ranging phase 2b study
Reviewed8 September 2026

What else is like Danuglipron?

Others in GLP-1 agonists, side by side.

If you're weighing Danuglipron, it's worth reading MariTide (maridebart cafraglutide), CT-388, and Pemvidutide in the same class.

YOU ARE HERE

DANUSmall molecule

Danuglipron

An experimental weight-loss pill whose development was stopped over a liver-injury signal.

Investigational

Dose: 40 up to 200 mg per dose
How often: Daily

MARI

MariTide (maridebart cafraglutide)

An experimental once-a-month obesity shot.

Investigational

Dose: 140 up to 420 mg per month (trial doses)
How often: Monthly

CT-388

An experimental weekly weight-loss shot in the tirzepatide family.

Investigational

Dose: 4 up to 24 mg per week (trial doses)
How often: Weekly

PEMVI

Pemvidutide

An experimental weekly shot for weight loss and fatty liver.

Investigational

Dose: 1.2 up to 2.4 mg per week (trial doses)
How often: Weekly

How Danuglipron compares to other GLP-1 peptides See all needle-free options

See the full GLP-1 comparison

Guides for this compound

How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Semaglutide vs Tirzepatide vs Retatrutide
One receptor, two, or three. Mechanism, trial weight loss, side effects, and real cost.

Sources

Pfizer, topline phase 2b results for oral danuglipron in adults with obesity(2023)
The trial met its primary endpoint, with placebo-adjusted weight reductions of 8 to 13 percent at 32 weeks. It also reported nausea up to 73 percent, vomiting up to 47 percent, and discontinuation rates above 50 percent across all doses against roughly 40 percent on placebo. Pfizer stated the twice-daily formulation would not advance to phase 3.
Efficacy and safety of danuglipron in adults with obesity, randomized placebo-controlled dose-ranging phase 2b study(2025)
The published version. The authors note that discontinuation due to adverse events was higher than anticipated across all treatment groups, including placebo.

Last reviewed 8 September 2026

Beyond these, 73 records are indexed. Browse the records